Flavivirus vaccines based on ChimeriVax technology contain the nonstructural genes of the yellow fever vaccine and the premembrane and envelope genes of heterologous flaviviruses, such as Japanese encephalitis and West Nile viruses. These chimeric vaccines induce both humoral and cell-mediated immunity. Mice were vaccinated with yellow fever, chimeric Japanese encephalitis virus (YF/JE), or chimeric West Nile virus (YF/WN) vaccines, followed by a secondary homologous or heterologous vaccination; the hierarchy and function of CD8 + T cell responses to a variable envelope epitope were then analyzed and compared with those directed against a conserved immunodominant yellow fever virus NS3 epitope. Sequential vaccination with heterologous chimeric flaviviruses generated a broadly cross-reactive CD8 + T cell response dependent on both the sequence of infecting viruses and epitope variant. The enhanced responses to variant epitopes after heterologous vaccination were not related to preexisting antibody or to higher virus titers. These results demonstrate that the sequence of vaccination affects the expansion of cross-reactive CD8 + T cells after heterologous chimeric flavivirus challenge.
dominant peptides, presented in the context of major histocompatability complex (MHC) class I by antigenpresenting cells, leads to clonal differentiation and proliferation of effector cells, followed by contraction and memory generation [12] [13] [14] [15] . Memory T cells generated against subdominant epitopes of one virus may demonstrate plasticity in antigen recognition after secondary heterologous challenge, leading to protective immunity or immunopathology [16] [17] [18] [19] . We previously demonstrated that sequential infection with different dengue virus serotypes induces sequence-specific expansion of dengue virus cross-reactive CD8 + T cells [20] . Prime-boost vaccinations using recombinant DNA vaccines or virus-like particles similarly enhance immune responses to inserted heterologous epitopes [21] [22] [23] [24] . The cocirculation and emergence of flaviviruses in many regions of the world point to the need for effective vaccination strategies against these viruses [1, 2] . Novel, NOTE. The first 7 sequences are from the envelope region (amino acid residues 4-12) of the respective flavivirus genome. The last sequence is from the nonstructural region (NS3 268-275) of the yellow fever 17D (YF17D) strain. The differences in amino acid sequence are shown in italics. The homology is with reference to JEE1 sequence. The major histocompatability complex (MHC) specificity for all the envelope peptides is H2-D b and for YF virus NS3 it is H2-K b . a Absence of homology because it is not from the envelope region of YF17D.
live attenuated chimeric flavivirus vaccines have been produced on a platform using the nonstructural and core backbone of the YF 17D vaccine and the premembrane and envelope genes of heterologous flaviviruses, including Japanese encephalitis, West Nile, and dengue viruses. These virus vaccines have demonstrated protection against homologous virus challenge in animal models and generation of adaptive B and T cell responses in human clinical trials [25] [26] [27] [28] [29] [30] . Neutralizing antibody responses to chimeric vaccine viruses have been shown to be specific to the virus from which the envelope gene is derived [31, 32] . CD8 + T cells have been found to be necessary for protection from primary dengue virus, West Nile virus, and Japanese encephalitis virus infections in mouse models; West Nile virus envelope-specific CD8 + T cells afford protection against lethal West Nile virus challenge [8, 9, 11, 33, 34] .
The potential of chimeric vaccines to generate cross-reactive CD8 + T cell responses to heterologous flaviviruses has not been studied. Here, we evaluated quantitatively and qualitatively the CD8 + T cell responses to a subdominant flavivirus cross-reactive T cell epitope on the envelope protein and to a conserved, immunodominant yellow fever virus NS3 epitope, after primary or heterologous secondary infection. We found that secondary vaccination with heterologous chimeric flavivirus vaccines generated an enhanced cross-reactive CD8 + T cell response that was dependent on the sequence of the infecting vaccine viruses. These results suggest that controlled exposure to multiple related flavivirus vaccines may lead to enhanced protection against related flaviviruses. [35] . K b and D b knockout mice (Taconic) were used to confirm MHC restriction of CD8 + T cell epitopes. For primary vaccinations, splenocytes were harvested on serial days after infection for acute responses and on day 28 for memory responses. To determine secondary CD8 + T cell responses, 4-6 weeks after primary vaccination, groups of 3-4 mice from each primary virus vaccination were inoculated with either homologous or heterologous viruses intraperitoneally with PFU of vaccine virus. 6 1 ϫ 10 Peptides. Crude peptides (20 mer overlapping by 10 amino acids) spanning the envelope region of Japanese encephalitis virus SA14-14-2 (GenBank accession number AAK11279) and peptide truncations were synthesized by the University of Massachusetts Medical School Peptide Core Facility. WNE1 is a D b -restricted CD8 + T cell epitope [11] . Biology Workbench blast search revealed homologous sequences for other flaviviruses (Table 1) . Variant envelope and yellow fever virus NS3 peptides were synthesized at 190% purity by AnaSpec.
MATERIALS AND METHODS

Mice
Generation of T cell lines and cytotoxic T cell assay. Spleens were obtained 7 days after homologous boost from mice vaccinated with either YF/WN or YF/JE vaccine. Single-cell suspensions were prepared as described elsewhere [20] . Cells were cultured in the presence of peptide (10 mg/mL) in Roswell Park Memorial Institute 1640 medium containing 10% fetal calf serum, 1% penicillin and streptomycin, mol/L mercap- toethanol, and 25 U/mL recombinant human interleukin 2 (BD Biosciences) at 37ЊC. Every 14 days, g-irradiated naive splenocytes were pulsed with peptide (10 mg/mL) and added at a 5:1 ratio of stimulators to responders.
51
Chromium release assays were performed as described elsewhere [36] . Intracellular cytokine detection assay. Peptide-specific IFN-g-producing and TNF-a-producing CD3 + CD8 + T cells were quantified by intracellular cytokine staining (ICS) assay [20] . Briefly, splenocytes per well were seeded in 96- 6 1 ϫ 10 well plates with 10 mg/mL peptide, medium alone, or PMA (50 ng/mL) plus ionomycin (500 ng/mL) and incubated for 5-6 h in the presence of 5 mL/mL of brefeldin A (GolgiPlug, BD Biosciences). Following wash and Fc blocking, cells were incubated with anti-mouse CD3-PerCP (145-2C11, BD Biosciences) and anti-mouse CD8a-fluorescein isothiocyanate (FITC) (5.3-C711, eBioscience). After fixation with BD Cytofix/ Cytoperm, washing with perm-wash buffer, and staining with Phycoerythrin (PE)-conjugated IFN-g (eBioscience) and allophycocyanin-conjugated TNF-a (BD Biosciences), cells were washed and resuspended in 1% paraformaldehyde and data acquired on a FACSCalibur flow cytometer. Data were analyzed with FlowJo software (Treestar). Background media frequencies were subtracted from peptide-stimulated cell frequencies.
Surface marker and pentamer staining. MHC-peptide pentamers and R-Phycoerythrin (RPE) label (ProImmune) were used according to the manufacturer's instructions. Briefly, splenocytes were incubated with pentamer, washed, and 6 1 ϫ 10 Fc-blocked with 2.4G2 (BD Biosciences). Cells were surface stained with RPE, PerCP-conjugated CD3, and FITC-labeled CD8. Following washing and fixation with 0.1% paraformaldehyde, the samples were acquired on a FACSCaliber flow cytometer, and data were analyzed using FlowJo Software. Adoptive transfer of serum. Mice were vaccinated with PFU of YF/JE vaccine. At 28 days after infection, serum 6 1 ϫ 10 samples were collected from YF/JE-immune mice or naive mice and heat inactivated. Naive mice were inoculated intraperitoneally with 150 mL of undiluted or diluted (1:10 in PBS) immune or naive serum and inoculated intraperitoneally with YF/ WN vaccine 24 h later. At 8 days after infection, splenocytes were harvested and analyzed for IFN-g response. Measurement of virus replication in affected organs. Mice were vaccinated with YF/JE vaccine; 3 and 7 days after infection, spleen, liver, brain, and serum were collected and stored at Ϫ70ЊC. Remaining mice were administered YF/WN vaccine 28 days after infection, and the same organs were collected and frozen 3 and 7 days after infection. Organs were homogenized in minimum essential medium, sonicated, and centrifuged. Virus titers were measured in supernatants by plaque assay as described elsewhere [35] .
Statistical analysis. Data were analyzed with a MannWhitney test using SigmaPlot/SigmaStat, and P values of р.05 were considered significant. The correlation between ICS and pentamer data was analyzed using Pearson rank correlation using Minitab program. The median values were obtained using Microsoft Excel.
RESULTS
Heterologous and conserved peptides used for in vitro stimulation. T cell epitopes against Japanese encephalitis virus have not been previously identified in C57Bl/6 mice. We used an IFN-g ELISPOT assay to screen peptide pools containing overlapping Japanese encephalitis virus envelope peptides in splenocytes from mice who had received YF/JE vaccine. We identified an optimal epitope, JEE1, a homologue of a D b -restricted West Nile virus envelope epitope [8] . Using JEE1 as the base sequence, homologous envelope sequences were identified for 7 other flaviviruses (Table 1) . JEE1-stimulated bulk cultures from YF/JE-immune mice showed recognition of JEE1 and WNE1 epitopes in chromium release assays (data not shown). Vaccination of K b and D b knockout mice with chimeric YF/JE vaccine confirmed that recognition of all 8 envelope gene variants was D b restricted (data not shown). We selected an immunodominant H-2k b -restricted yellow fever virus NS3-specific CD8 + T cell epitope [7] whose sequence is conserved among all 3 viruses for comparison to the variable epitope.
Kinetics of epitope-specific T cell IFN-g responses during primary and secondary flavivirus vaccinations. Epitope-specific T cell responses may differ during primary and secondary virus infection [20] [21] [22] [23] . We therefore examined the kinetics of T cell responses after primary and secondary infections. The peak IFN-g responses to the conserved NS3 and variable envelope epitopes after primary vaccination were observed at 7 and 9 days after infection for NS3, and 9 days after infection for envelope epitopes ( Figure 1A ). The peak IFN-g responses Figure 1 . Kinetics of interferon g (IFN-g) production after primary or secondary flavivirus vaccination. C57BL/6 mice were vaccinated with PFU of chimeric yellow fever virus-Japanese encephalitis virus 6 1 ϫ 10 (YF/JE) or yellow fever 17D virus (YF17D). Splenocytes were harvested on indicated days and stimulated in vitro with all envelope variant peptides, and the conserved NS3 epitope and IFN-g production was measured by enzyme-linked immunospot (ELISPOT) assay. Four to six weeks after primary vaccination, mice were vaccinated with PFU of yellow fever virus, 6 1 ϫ 10 YF/JE virus, or chimeric West Nile (YF/WN) virus; at 3, 4, 5, 6, and 7 days after secondary vaccination, splenocytes were harvested and ELISPOT assay was performed as above. The figure shows representative data for primary YF/JE virus vaccination (A) and primary YF/JE virus vaccination followed by secondary YF/WN virus vaccination (B ). Each data point represents an individual mouse. Bars represent median values for each group. WNE1 (circles), JEE1 (triangles), YF virus NS3 (squares).
to both envelope and NS3 epitopes were observed 5 days after the secondary vaccination ( Figure 1B ). For subsequent experiments, primary and secondary responses were therefore analyzed at 8 and 5 days after infection, respectively. Despite greater sequence homology of the dengue virus envelope variants than the YFE1 to JEE1 variants, we found that in vitro stimulation with dengue virus envelope variants (56%-67% homology) led to lower IFN-g responses than did the YFE1 variant (56% homology) (not shown). Therefore, we included the JEE1, WNE1, YFE1, and SLEE1 peptides and the conserved NS3 peptide for subsequent studies.
Cytokine production by CD8 + T cells after primary and secondary flavivirus vaccinations. To determine whether the effects of sequential infection differ for variable epitopes versus conserved epitopes, we assessed IFN-g-producing and TNF-a-producing cells in response to stimulation with yellow fever virus NS3 peptide and the variable flavivirus envelope peptides after primary and secondary homologous and heterologous vaccination with yellow fever, YF/JE, and YF/WN vaccines. The TNF-a-producing cellular response to envelope and NS3 peptide sequences was negligible in both the primary and secondary infections (not shown). However, an increase in the number of IFN-g-producing cells was observed in response to envelope and yellow fever virus NS3 epitopes when a particular primary vaccination was followed by heterologous vaccination (Figure 2A and 2B ; Table 2 ). Similar to that found for dengue virus, the effect of sequential infection on the epitope-specific T cell response was dependent on the specific sequence of vaccinations [20] . For example, primary vaccination with YF/JE vaccine elicited increased IFN-g responses after heterologous yellow fever or YF/WN vaccine challenge (Figure 2A ). In contrast, there was little change in IFN-g production from CD8 + T cells in mice vaccinated with primary YF/WN vaccine followed by heterologous yellow fever or YF/JE vaccine challenge. These changes were not only virus sequence-dependent but also epitope variant-dependent. Although the overall increase in responses were modest for West Nile virus E1, Japanese encephalitis virus E1, yellow fever virus E1, and yellow fever virus NS3 epitopes in those mice that received primary yellow fever vaccination followed by YF/JE or YF/WN vaccine challenge, there was a significant increase in the response to the SLEE1 epitope (Figure 2A and 2B ; Table 2 ).
Frequency of CD8 + T cells specific for variable envelope and conserved NS3 epitopes after primary and secondary flavivirus vaccinations. To determine whether the frequency of IFN-g producing cells represented the majority of epitope-specific cells, we measured epitope-specific cells with pentamers of MHC loaded with WNE1, JEE1, or yellow fever virus NS3. After primary vaccination with YF/JE or YF/WN vaccines, there was an increase in the frequency of pentamer-binding cells from day 8 to weeks 4-6. A similar increase was not seen after primary yellow fever vaccination ( Figure 3 ; Table 2 ). We also observed a boost in the frequency of epitope-specific cells after secondary heterologous vaccination. This boost appeared to be virus sequence-specific. For example, primary vaccination with YF/JE or yellow fever vaccine, followed by heterologous vaccination, boosted WNE1 and JEE1 epitope-specific T cell frequencies, whereas primary vaccination with YF/WN vaccine did not show a similar effect. We also detected epitope-specific differences in T cell frequencies for the same vaccination regimen. For example, primary YF/WN vaccination followed by NOTE. "Yes" indicates a statistically significant different response, compared with the reference group. Groups of mice were vaccinated with chimeric Japanese encephalitis virus (YF/JE), chimeric West Nile virus (YF/WN), or yellow fever 17D (YF17D) virus. Secondary vaccinations with homologous or heterologous virus were performed 28 days after primary vaccination. Splenocytes were examined for IFN-g production and pentamer binding at 8 and 28 days after vaccination for acute and memory primary responses, respectively, and at 5 days after secondary vaccination. JEE1, Japanese encephalitis virus E1; ND, no data; SLE E1, Saint Louis encephalitis virus E1; WNE1, West Nile E1; YFE1, yellow fever E1; YFNS3, yellow fever virus NS3.
heterologous vaccination with YF/JE vaccine induced a significant increase in the frequency of yellow fever virus NS3-specific CD8 + T cells ( ) but did not demonstrate any increase P p .011 in WNE1-or JEE1-specific CD8 + T cells ( Figure 3 ; Table 2 ).
Role of T cell functional avidity.
The avidity of the T cell receptor for peptide-MHCs affects both the quality and quantity of a given T cell response. We hypothesized that the differences seen in JEE1 and WNE1 pentamer binding and cytokine induction might be a result of differences in avidity. We therefore measured IFN-g responses to different concentrations of JEE1, WNE1, and yellow fever virus NS3 peptides (functional avidity). Primary vaccination with YF/JE vaccine-as well as primary YF/JE vaccination followed by secondary YF/WN vaccination-exhibited similar patterns of functional avidity for both envelope epitopes with peak responses occurring at peptide concentrations of 0.1 and 1 mg/mL, respectively, and reaching a nadir at a concentration of 0.001 mg/mL after primary vaccination and 0.01 mg/mL after secondary heterologous vaccination ( Figure 4A and 4B) . For both primary and secondary vaccinations, IFN-g responses to the NS3 epitope did not diminish, even at 0.001 mg/mL, indicating a higher functional avidity compared with the JEE1 and WNE1 epitopes.
Antibody-dependent enhancement is not responsible for the increased T cell response after sequential heterologous flavivirus vaccinations. IFN-g ICS and pentamer binding results indicated that when primary vaccination with YF/JE vaccine was followed by heterologous vaccination with YF/WN vaccine or yellow fever 17D (YF17D), there was an increase in frequency and cytokine production by epitope-specific CD8 + T cells. In heterologous dengue virus infection, preexisting antibody from the primary infection is theorized to enhance infection of FcgRexpressing cells, leading to increased viremia and disease severity after secondary infection. To evaluate the possible role played by preexisting antiflavivirus antibodies in enhancing T cell responses [37] , we conducted passive vaccination studies with YF/JE-immune or naive serum, followed by YF/WN vaccination. We found no significant difference in the IFN-g response by splenocytes from mice that received YF/JE-immune serum (either undiluted or at 1:10 dilution) compared with splenocytes from mice that received naive serum ( Figure 5 ). Viral titers in primary and secondary infections. We collected serum, spleen, liver, and brain from mice on days 3 and 7 after primary and secondary vaccinations, respectively. We were unable to detect infectious virus in any of these tissues at 1 ϫ 10 splenocytes were harvested and stimulated in vitro with the envelope (E) variants, and the conserved YFNS3 peptide and interferon g (IFN-g) production were measured using intracellular cytokine staining (y-axis). Error bars represent the standard error of the mean. Each bar represents mean data from single mice ( ) run in 2 separate experiments. n p 8 either time point, suggesting that the increased epitope-specific T cell frequencies were not related to increased virus antigen (data not shown).
DISCUSSION
Secondary infection or vaccination with related or unrelated pathogens can result in either protective immunity or immunopathology [16, 17, [38] [39] [40] . There have been several studies exploring immune responses to chimeric flaviviruses [8, 9] , cross-reactive immunity [26] , and the benefits of recombinant vaccines in prime-boost strategies [21] [22] [23] [24] . However, the effect of sequential vaccination on CD8 + T cell responses using chimeric viruses for Japanese encephalitis and West Nile viruses has not, to our knowledge, previously been studied. We identified and characterized a new Japanese encephalitis virus envelope-specific CD8 + T cell epitope, which is a variant of an H-2D b restricted West Nile virus epitope [8] . Using this epitope as a reference, we identified additional flavivirus variant envelope epitopes. The majority of these variants fit the H-2D b binding motif, which is composed of asparagine at P5, and methionine, isoleucine, or leucine at P9; however, amino acid changes at other positions (especially P2) may adversely affect peptide binding [41, 42] . Surprisingly, YFE1-which shared the lowest homology to JEE1 with only 5 of 9 amino acids conserved and with a nonconservative change at P5 from asparagine to aspartic acid-still retained substantial functional cross-reactivity, whereas the more closely homologous dengue virus epitopes did not [43, 44] .
The peak responses to envelope and NS3 epitopes were detected on day 5 after secondary vaccination. Given the more rapid increase in epitope-specific cells when compared with that seen after primary vaccination, these findings suggest that cross-reactive memory CD8 + T cells are responsible for this early response. Circulating memory cells have been shown to have a lower activation threshold than do naive T cells and may therefore be preferentially activated at a much faster rate, when presented with the same or cross-reactive epitope in the context of the appropriate MHC [12] [13] [14] . Primary vaccination with YF/JE vaccine resulted in memory CD8 + T cells that were able to recognize both novel envelope variants and the conserved yellow fever virus NS3 epitopes after homologous and heterologous secondary vaccinations, which suggests that this type of sequential vaccination strategy can generate a memory pool with broad spectrum immunity (CD8 + T cells, as well as neutralizing antibody responses) as seen in other flavivirus animal model systems [20, 45] . Similarly to what has been seen in humans, administration of chimeric yellow fever dengue virus 2 vaccine to yellow fever-immune subjects led not only to enhanced levels of dengue virus 2-specific neutralizing antibodies but also induced a greater breadth of cross-reactive neutralizing antibody directed against other dengue virus serotypes [32] .
Primary vaccination with YF/WN vaccine did not seem to generate a pattern of cross-reactivity in response to the envelope variants, as was seen with primary YF/JE vaccine. A possible explanation for the virus sequence-specific differences in the generation of epitope-specific responses may relate to differing peptide-MHC avidity among different epitope variants. However, this did not seem to be the case because the functional avidity for the JEE1 and WNE1 peptides was similar after primary YF/JE vaccination and after primary YF/JE vaccination, followed by secondary YF/WN vaccination. Alternatively, differences in the frequencies of cross-reactive memory CD4 + T cells generated after primary vaccination with YF/JE and YF/ WN vaccines may alter the ability to provide help to CD8 + T cells after secondary heterologous vaccination, as has been suggested in our previous studies of dengue virus [46] . Using mathematical modeling, Zou et al [47] have suggested that, to generate a more broadly cross-reactive immune response against all 4 dengue virus serotypes, the optimal dengue virus vaccine to afford tetravalent protection would be a polytopic vaccine that includes subdominant epitopes for priming.
We found a discrepancy in the frequency and functionality of the antigen-specific T cells, in which the frequency of cells measured by pentamer binding was generally higher than that seen in IFN-g ICS (Table 2 ). These differences likely result from additional unmeasured effector functions (eg, cytolytic function or other cytokines). We have previously shown that CD8 + T cells from humans vaccinated with live attenuated dengue virus vaccines are able to secrete varying quantities of IFN-g, TNFa, and MIP-1b [15] . In this model, we were not able to measure appreciable amounts of TNF-a in response to peptide stimulation, and a reliable murine anti-MIP-1b antibody was not available. Although we were able to measure cross-reactive cytotoxic responses to both JEE1 and WNE1 in JEE1-and WNE1-stimulated bulk cultures raised from YF/JE-and YF/WNimmunized mice (not shown), we did not evaluate cytolytic function directly ex vivo. The avidity of T cells for the pMHC has been shown to play a key role in the type of response by the epitope-specific T cells [48] [49] [50] . However, results of peptide dose response experiments do not suggest that the differences in the memory response to envelope variants are related to differences in T cell avidity for variant pMHCs, because both envelope epitopes had similar and lower functional avidity compared with that of the conserved yellow fever virus NS3 epitope. Previous studies have demonstrated that variant epitopes of low avidity are more likely to be cross-reactive, whereas immunodominant epitopes such as the yellow fever virus NS3 tend to have tight binding to peptide-MHC [49, 50] .
In vitro enhancement of dengue virus infection in the presence of heterologous dengue virus-specific antibody leads to increased uptake by FcgR-expressing cells [37] . In vivo support of the role of enhancing antibodies in the pathogenesis of dengue virus infection remains controversial, but a resulting increase in virus burden might enhance antigen presentation to memory cross-reactive T cells, leading to activation and increased cytokine production [37] . Our passive transfer studies using YF/JE immune serum followed by YF/WN vaccination do not support this mechanism for the enhanced IFN-g response in heterologous vaccination after primary YF/JE vaccination Figure 5 ). The absence of detectable infectious virus in the serum and tissues of mice who received YF/JE vaccination, followed by secondary YF/WN vaccination, also do not support a role for differences in virus burden as a mechanism for enhanced T cell responses.
Our findings suggest that cross-reactive CD8 + T cells generated during sequential immunization with heterologous chimeric flavivirus vaccines depend on the primary vaccine virus, as well as on the sequence of vaccination. Mice that received primary YF/JE vaccination had greater numbers of epitopespecific CD8 + T cells, and these cells further expanded in frequency and effector function after secondary vaccination with the heterologous virus vaccines, YF/WN vaccine and YF17D. Therefore, the above strategy of vaccination may result in the generation of increased epitope-specific cross-reactive T cells that are protective. Although CD8 + T cell responses in humans differ from those in mice, this study indicates that certain sequences of vaccination may augment T cell responses more than others. Additional research to evaluate the role of other viral and host factors may provide useful insight into the significance of sequential vaccination with chimeric flaviviruses.
